In vitro and in vivo study of gal-os self-assembled nanoparticles for liver-targeting delivery of doxorubicin

Journal of Pharmaceutical Sciences

Volumn 103, Issue 3, 2014, Pages 987-993

  Guo, Hejian ^a   Zhang, Dianrui ^a   Li, Tingting ^a   Li, Caiyun ^a   Guo, Yuanyuan ^a   Liu, Guangpu ^a   Hao, Leilei ^a   Shen, Jingyi ^a   Qi, Lisi ^a   Liu, Xinquan ^a   Luan, Jingjing ^a   Zhang, Qiang ^b  

^a SHANDONG UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

doxorubicin; Drug delivery systems; Drug targeting; liver targeting; Nanoparticles; O carboxymethyl chitosan; Pharmacodynamics; pharmacokinetics; tissue distribution

Indexed keywords

CHITOSAN DERIVATIVE; DOXORUBICIN; GAL OS SELF ASSEMBLED NANOPARTICLE; GALACTOSYLATED O CARBOXYMETHYL CHITOSAN GRAFT STEARIC ACID; NANOPARTICLE; STEARIC ACID DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIBIOTIC; CHITOSAN; DRUG CARRIER; GALACTOSE; O-CARBOXYMETHYLCHITOSAN; STEARIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CIRCULATION TIME; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; DRUG UPTAKE; IN VITRO STUDY; IN VIVO STUDY; LIVER TARGETING DRUG DELIVERY SYSTEM; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PH; PLASMA CONCENTRATION-TIME CURVE; RAT; TARGET ORGAN; TIME TO MAXIMUM PLASMA CONCENTRATION; TISSUE DISTRIBUTION; ZETA POTENTIAL; ANALOGS AND DERIVATIVES; ANIMAL; CHEMISTRY; DRUG FORMULATION; GLYCOSYLATION; HEART MUSCLE; INBRED MOUSE STRAIN; LIVER; MALE; METABOLISM; RANDOMIZATION; SOLUBILITY; SPLEEN; ULTRASTRUCTURE; WISTAR RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CHITOSAN; DOXORUBICIN; DRUG CARRIERS; DRUG COMPOUNDING; GALACTOSE; GLYCOSYLATION; HYDROGEN-ION CONCENTRATION; LIVER; MALE; MICE; MICE, INBRED STRAINS; MYOCARDIUM; NANOPARTICLES; RANDOM ALLOCATION; RATS; RATS, WISTAR; SOLUBILITY; SPLEEN; STEARATES; STEARIC ACIDS; TISSUE DISTRIBUTION;

EID: 84894448129     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23875     Document Type: Article

References (16)

1. Li C, Zhang D, Guo H, Hao L, Zheng D, Liu G, Shen J, Tian X, Zhang Q,. 2013. Preparation and characterization of galactosylated bovine serum albumin nanoparticles for liver-targeted delivery of oridonin. Int J Pharm 448 (1): 79-86.
2. Zhou N, Zan X, Wang Z, Wu H, Yin D, Liao C, Wan Y,. 2013. Galactosylated chitosan-polycaprolactone nanoparticles for hepatocyte-targeted delivery of curcumin. Carbohydr Polym 94 (1): 420-429.
3. Abraham SA, Waterhouse DN, Mayer LD, Cullis PR, Madden TD, Bally MB,. 2005. The liposomal formulation of doxorubicin. Method Enzymol 391: 71-97.
4. Cambõn A, Rey-Rico A, Mistry D, Brea J, Loza MI, Attwood D, Barbosa S, Alvarez-Lorenzo C, Concheiro A, Taboada P, Mosquera V,. 2013. Doxorubicin-loaded micelles of reverse poly(butylene oxide)-poly(ethylene oxide)-poly(butylene oxide) block copolymers as efficient "active" chemotherapeutic agents. Int J Pharm 445 (1-2): 47-57.
5. Shmeeda H, Tzemach D, Mak L, Gabizon A,. 2009. Her2-targeted pegylated liposomal doxorubicin: Retention of target-specific binding and cytotoxicity after in vivo passage. J Control Release 136 (2): 155-160.
6. Weng L, Le HC, Lin J, Golzarian J,. 2011. Doxorubicin loading and eluting characteristics of bioresorbable hydrogel microspheres: In vitro study. Int J Pharm 409 (1-2): 185-193.
7. Lee GY, Park K, Kim SY, Byun Y,. 2007. MMPs-specific PEGylated peptide-DOX conjugate micelles that can contain free doxorubicin. Eur J Pharm Biopharm 67 (3): 646-654.
8. Yu J-M, Li Y-J, Qiu L-Y, Jin Y,. 2008. Self-aggregated nanoparticles of cholesterol-modified glycol chitosan conjugate: Preparation, characterization, and preliminary assessment as a new drug delivery carrier. Eur Polym J 44 (3): 555-565.
9. Hu F-Q, Wu X-l, Du Y-Z, You J, Yuan H,. 2008. Cellular uptake and cytotoxicity of shell crosslinked stearic acid-grafted chitosan oligosaccharide micelles encapsulating doxorubicin. Eur J Pharm Biopharm 69 (1): 117-125.
10. Xiao K, Li Y, Luo J, Lee JS, Xiao W, Gonik AM, Agarwal RG, Lam KS,. 2011. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials 32 (13): 3435-3446.
11. Cho H-J, Yoon I-S, Yoon HY, Koo H, Jin Y-J, Ko S-H, Shim J-S, Kim K, Kwon IC, Kim D-D,. 2012. Polyethylene glycol-conjugated hyaluronic acid-ceramide self-assembled nanoparticles for targeted delivery of doxorubicin. Biomaterials 33 (4): 1190-1200.
12. Xiao K, Luo J, Li Y, Lee JS, Fung G, Lam KS,. 2011. PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma. J Control Release 155 (2): 272-281.
13. Cheng R, Meng F, Deng C, Klok H-A, Zhong Z,. 2013. Dual and multi-stimuli responsive polymeric nanoparticles for programmed site-specific drug delivery. Biomaterials 34 (14): 3647-3657.
14. Caron WP, Lay JC, Santos C, Merricks EP, Nichols TC, Ramanathan RK, Gehrig PA, Zamboni WC,. 2012. Relationship between interspecies variability in the mononuclear phagocyte system and nanoparticle pharmacokinetics. Eur J Cancer 48: 20-20.
15. Liu GP, Zhang DR, Jiao Y, Guo HJ, Zheng DD, Jia LJ, Duan CX, Liu Y, Tian XN, Shen JY, Li CY, Zhang Q, Lou HX,. 2013. In vitro and in vivo evaluation of riccardin D nanosuspensions with different particle size. Colloid Surf B 102: 620-626.
16. Jia LJ, Zhang DR, Li ZY, Duan CX, Wang YC, Feng FF, Wang FH, Liu Y, Zhang QA,. 2010. Nanostructured lipid carriers for parenteral delivery of silybin: Biodistribution and pharmacokinetic studies. Colloid Surf B 80 (2): 213-218.